Is Bio-Techne Corporation (TECH) a Buy, Sell, or Hold?
NASDAQ : TECH
Bio-Techne Corporation
$71.6 USD
-$0.17 (-0.24%)
- Volume
- 2.07M
- Average Volume
- 4.79M
- Market Capitalization
- $11.21B
- P/E Ratio
- 100.85
- Dividend Yield
- 0.45%
- Price Target
- $73.00
- Year High
- $72.16
- Year Low
- $43.20
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.45
- Current Ratio
- $4.49
Company Overview
NASDAQ
Kim Kelderman
Biotechnology
Healthcare
TECH
3100
US
USD
Liquidity Metrics
0.14
4.49
3.18
1.37
0.45
Sales & Valuation
$1.22B
9.26
5.35
41.58
1.73
Profitability
$0.46
$73.4M
9.05%
12.15%
5.49%
4.30%
P/E Metrics
100.85
-6.98
-6.98
Analyst Price Target & Rating
$73.00
$79.00
$50.00
3/5
26 Analysts
-1.92%
Financial Health Scores
16.01
8/9
$534.77M
$2.55B
$465.3M
$157.65M
Key Metrics (TTM)
$11.29B
9.33
43.77
4.49
5.49%
4.75%
0.98%
2.40%
$14.54
219 days
Company Executives
| Name | Title |
|---|---|
| Dylan Malayter | Senior Vice President of Reagent Solutions Division |
| Gerry Andros | Vice President of Sales and Marketing |
| Luca Cicchetti | Managing Director |
| Martin Wirtz | Senior Vice President of Strategy & Corporate Development |
| Steve Crouse | President of Diagnostics & Spatial Biology Segment |
| Cheryl Bethune | Senior Vice President & Chief Human Resources Officer |
| Shane Bohnen | Senior Vice President, General Counsel, Corporate Secretary & Chief Sustainability Officer |
| James T. Hippel | Executive Vice President of Finance & Chief Financial Officer |
| Kim Kelderman | Chief Executive Officer, President & Director |
| William A. Geist | President of Protein Sciences Segment |
| David Clair | Vice President of Investor Relations |
| Bernie Andruss | Senior Vice President of Bio-Techne Diagnostics Division |
| Gary J. Latham | Vice President & Chief Technology Officer |
Poll Results
No votes yet today — be the first to share your view!
About Bio-Techne Corporation (NASDAQ:TECH) Stock
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifyi ... ng proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Bio-Techne Corp $TECH Holdings Lowered by Bessemer Group Inc.
2026-07-22 04:17:48
Bessemer Group Inc. lowered its stake in Bio-Techne Corp (NASDAQ: TECH) by 13.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 61,962 shares of the biotechnology company's stock after selling 9,722 shares during the quarter. Bessemer Group Inc.'s holdings in
IXJ vs. RSPH: Which Healthcare ETF Is the Better Buy?
2026-07-21 13:32:42
IXJ offers a higher dividend yield and lower volatility with global exposure, while RSPH's equal-weight approach posted a stronger 1-year return.
Bio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein Portfolio
2026-07-08 06:30:00
Advancing Scalable Reproducible Cell Therapy and Advanced Cell Culture Workflows New heat-stable and hyperactive proteins across the fibroblast growth factor and interleukin cytokine families expand the R&D Systems™ AI-Engineered Designer Protein portfolio AI-guided protein design supports improved consistency, performance and scalability in complex cell culture workflows Engineered signaling proteins help address key challenges in scaling cell therapy from discovery through manufacturing MINNEAPOLIS, July 8, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced the launch of new additions to its R&D Systems™ AI-Engineered Designer Protein portfolio, designed to improve reproducibility and performance across advanced cell culture and cell therapy development workflows. The R&D Systems AI-Engineered Designer Protein platform enables the design and creation of new protein-based solutions to help researchers overcome current variability and scalability challenges in advanced cell culture by improving the stability and activity of critical reagents.
2026-07-06 12:17:00
BALA CYNWYD, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.
2026-07-02 05:31:48
MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Bio-Techne (NASDAQ: TECH) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Merck. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.
2026-07-02 05:31:00
MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Bio-Techne (NASDAQ: TECH) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Merck.
2026-06-30 13:13:00
BALA CYNWYD, Pa., June 30, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.
2026-06-29 16:21:00
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Bio-Techne Corporation (NasdaqGS: TECH) to Merck KGaA. Under the terms of the proposed transaction, shareholders of Bio-Techne will receive $73.00 in cash for each share of Bio-Techne that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or.
Frequently Asked Questions
-
What is the current Bio-Techne Corporation (TECH) stock price?
-
Bio-Techne Corporation(NASDAQ:TECH) stock price is $71.6 in the last trading session. During the trading session, TECH stock reached the peak price of $72.16 while $43.2 was the lowest point it dropped to. The percentage change in TECH stock occurred in the recent session was --0.24% while the dollar amount for the price change in TECH stock was -$0.17.
-
TECH's industry and sector of operation?
-
The NASDAQ listed TECH is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of TECH?
-
Dylan Malayter | Senior Vice President of Reagent Solutions Division
Gerry Andros | Vice President of Sales and Marketing
Luca Cicchetti | Managing Director
Martin Wirtz | Senior Vice President of Strategy & Corporate Development
Steve Crouse | President of Diagnostics & Spatial Biology Segment -
How many employees does TECH have?
-
Number of TECH employees currently stands at 3100. TECH operates from 614 McKinley Place N.E., Minneapolis, MN 55413, US.
-
Link for TECH official website?
-
Official Website of TECH is: https://www.bio-techne.com
-
How do I contact TECH?
-
TECH could be contacted at phone #612 379 8854 and can also be accessed through its website. TECH operates from 614 McKinley Place N.E., Minneapolis, MN 55413, US.
-
How many shares of TECH are traded daily?
-
The average number of TECH shares traded daily for last 3 months was 4.79M.
-
What is the market cap of TECH currently?
-
The market value of TECH currently stands at $11.21B with its latest stock price at $71.6